Wellnex Life Ltd
Wellnex Life Limited is an Australia-based health and wellness company, which is engaged in the consumer healthcare business.
The business
Wellnex Life Limited is an Australia-based health and wellness company, which is engaged in the consumer healthcare business. The Company is developing, licensing, and marketing registered products and brands to customers in the healthcare market segment. Its brands include Wakey Wakey, Nighty Night, Pharmacy Own, Mr Bright and Pain Away. The Company has intellectual property (IP)-licensing agreements with Haleon and Arrotex. The Company, through a joint venture with OneLife Botanical and Chemist Warehouse for SAS-B medicinal cannabis under the Wellness Life brand. It has launched a Therapeutic Goods Administration (TGA)-approved soft gel liquid paracetamol product in a jointly owned brand with retailer Chemist Warehouse under the Wagner Liquigesic brand. Mr Bright is a natural tooth whitening brand, which is being sold in the United Kingdom through Boots and TJ Maxx retail stores and is available online domestically.
Small Caps Research
No research on Wellnex Life Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise WNX based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Wellnex Life directors commit $1.5m to current entitlement offer
The directors of diverse consumer healthcare business Wellnex Life (ASX: WNX) have committed to subscribe for a minimum of $1.5 million as part of the company’s current entitlement offer. The offer is part of the company’s growth strategy, which includes a proposed listing on the AIM market of the London Stock Exchange. Funds raised and […]
Wellnex Life secures $14.3m for dual listing on London Stock Exchange
Wellnex Life (ASX: WNX) has secured conditional binding commitments to raise $14.3 million to fund its proposed dual listing on the London Stock Exchange’s (LSE) Alternative Investment Market (AIM) next month. The company has received interest from UK and Australian institutions and sophisticated investors for a non-renounceable pro-rata entitlement offer of one new Wellnex share […]
Wellnex Life raises $9m ahead of proposed London Stock Exchange AIM listing
Healthcare business Wellnex Life (ASX: WNX) has received initial conditional binding commitments of $9 million to support its proposed dual listing on the AIM sub-market of the London Stock Exchange (LSE). After receiving significant interest from UK-based institutions and sophisticated investors, the company launched the 1:1 non-renounceable entitlement offer it had previously announced earlier this […]
Wellnex Life expands global reach with UK market entry and new product approval
Wellnex Life (ASX: WNX) has achieved another breakthrough in its expansion plans with a new market authorisation (MA) for its liquid paracetamol plus caffeine soft gel. The MA comes after Wellnex made a successful submission to Australia’s Therapeutic Goods Administration for the latest addition to its product range. The company had previously been granted MAs […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.